At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections, where you are valued, accepted and respected for who you are,
Company Description At Syngenta Crop Protection, were pioneering solutions that safeguard global food security while championing sustainable agriculture. As a world market leader headquartered in Switzerland, we empower farmers with innovative crop protection technologies that defend against natures
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Salary Range:CHF169,400.00 - CHF314,600.00 Job Description Summary#LI-Hybrid Internal Title: TA Head, PKS Immunology Location: Basel We are seeking an accomplished and visionary scientific leader to join us as TA Head, PK Sciences (PKS) Immunology. In this
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections, where you are valued, accepted and respected for who you are,
Please note that we can only accept applicants who are eligible to work in Europe or in possession of a valid work permit. Second Engineer River - Nautic Viking (NYSE: VIK) was founded in 1997 and
# Therapeutic Area Head, PK Sciences – ImmunologyREQ- Jul 28, 2026SwitzerlandAvailable in:English# Summary#LI-Hybrid Internal Title: TA Head, PKS Immunology Location: Basel We are seeking an accomplished and visionary scientific leader to join us as TA Head,
Viking (NYSE: VIK) is a global leader in experiential travel with a fleet of more than 100 ships, exploring 21 rivers, five oceans and all seven continents. Designed for curious travelers with interests in science, history,
Manager & Senior Manager in Life Sciences Quality Management Consulting Grow here. Go further. Zürich Per Agreement 100% Advisory Everyone welcome ID: WD Your Impact Help sell, lead and, together with the team, deliver high-impact projects
Please note that we can only accept applicants who are eligible to work in Europe or in possession of a valid work permit. Trainee Cook River – Europe Viking (NYSE: VIK) was founded in 1997
About the BIIE The Botnar Institute of Immune Engineering is an independent, non-profit research institute dedicated to transforming global child and adolescent health. Operating in strategic partnership with ETH Zurich and the University of Oxford, we